Editas Medicine (EDIT) Price & Analysis

Compare

3,500 Followers

EDIT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.91 - $4.12

Previous CloseN/A

Volume963.61K

Average Volume (3M)2.17M

Market Cap

$245.48M

Enterprise Value$85.01M

Total Cash (Recent Filing)$178.50M

Total Debt (Recent Filing)$77.81M

Price to Earnings (P/E)―

Beta2.48

Next Earnings

Nov 10, 2025

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.63

Shares Outstanding89,920,166

10 Day Avg. Volume2,149,565

30 Day Avg. Volume2,170,924

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.35

Enterprise Value/Revenue2.19

Enterprise Value/Gross Profit2.37

Enterprise Value/Ebitda-0.38

Forecast

1Y Price Target

$4.14

Price Target Upside56.23% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Financial PositionThe company has approximately $178.5 million in cash, cash equivalents, and marketable securities, with a cash runway expected into the second quarter of 2027.

Partnerships And Milestone PaymentsThe first IND/CTA was accepted for the CD19+ HD Allo CAR-T program as part of the collaboration with Bristol Myers Squibb, triggering a milestone payment to Editas.

Preclinical DataEditas has completely re-positioned as an in vivo editing company and has recently shown highly promising preclinical data from their Sickle Cell Disease (SCD) and liver programs.

Bears Say

Clinical Development DelaysThe long road to initial clinical data remains a key holdup of the stock, which is why the HOLD rating is reiterated.

Clinical Trial RisksRisks include inability to advance candidates in clinical trials, most notably in sickle cell disease and beta-thalassemia.

Financial LossesEditas reported a net loss of $53.2 million, driven by expenses including R&D, SG&A, and a restructuring charge.

Editas Medicine News

Editas Medicine price target raised to $5 from $3 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Editas Medicine (EDIT) to $5 from $3 and keeps a...

15d ago

EDIT

Editas Medicine price target raised to $6 from $4 at Baird

Baird raised the firm’s price target on Editas Medicine (EDIT) to $6 from $4 and keeps an Outperform...

17d ago

EDIT

Editas Medicine reports Q2 EPS (63c), consensus (38c)

Reports Q2 revenue $3.58M, consensus $1.8M. “We made good progress in executing our strategy in the second quarter,...

17d ago

EDIT

Editas Medicine: Strategic Position Balances Cautious Development and Financial Stability

JonesTrading analyst Soumit Roy has maintained their neutral stance on EDIT stock, giving a Hold rating yesterday. Soumit...

14d ago

EDIT

Editas Medicine Inc. Faces Significant Business Risks: Key Factors for Investors to Watch

Editas Medicine Inc. (EDIT) has disclosed a new risk, in the Regulation category. Editas Medicine Inc. faces significant...

16d ago

EDIT

Editas Medicine Reports Q2 2025 Progress and Financials

Editas Medicine Inc. ( ($EDIT) ) has released its Q2 earnings. Here is a breakdown of the information...

16d ago

EDIT

Editas Medicine Unveils Promising Gene Editing Data

Editas Medicine ( ($EDIT) ) just unveiled an update. On June 12, 2025, Editas Medicine announced new in...

3M ago

EDIT

Promising Outlook for Editas Medicine: Strong Preclinical Data and Projected Financial Success

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Editas Medicine (EDIT – Research Report) today and...

3M ago

EDIT

Editas says levels of HBG1/2 promoter editing in hematopoietic stem cells

Editas Medicine (EDIT) shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic...

3M ago

EDIT

Editas Medicine Stockholders Approve Key Amendments

Editas Medicine ( ($EDIT) ) just unveiled an update. At the 2025 Annual Meeting of Stockholders held on...

3M ago

EDIT

Prime Medicine price target lowered to $12 from $16 at Chardan

Chardan analyst Geulah Livshits lowered the firm’s price target on Prime Medicine (PRME) to $12 from $16 and...

3M ago

EDIT

PRME

Cautious Outlook on Editas Medicine: Hold Rating Amidst Preclinical Progress and Financial Considerations

JonesTrading analyst Soumit Roy has maintained their neutral stance on EDIT stock, giving a Hold rating on May...

4M ago

EDIT

Promising Preclinical Data and Market Opportunities Drive Buy Rating for Editas Medicine

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Editas Medicine (EDIT – Research Report) today and...

4M ago

EDIT

Editas Medicine Reports Q1 2025 Progress and Financials

Editas Medicine Inc. ( ($EDIT) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

EDIT

EDIT FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was $0.91 and its highest was $4.12 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is $245.48M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Nov 10, 2025 which is in 72 days.

How were Editas Medicine Inc’s earnings last quarter?

Editas Medicine Inc released its earnings results on Aug 12, 2025. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.239.

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate is -0.3.

How many shares outstanding does Editas Medicine Inc have?

Editas Medicine Inc has 89,920,166 shares outstanding.

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Editas Medicine Inc reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went up 34.498%.

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in EDIT

Editas Medicine Stock Smart Score

Outperform

Fundamentals

Return on Equity

-188.58%

Trailing 12-Months

Asset Growth

-45.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine (EDIT) is a biotechnology company focused on developing transformative genomic medicines using its proprietary CRISPR gene-editing technology. The company operates primarily in the field of genetic medicine, targeting diseases caused by genetic mutations, including inherited retinal diseases and other serious conditions. Editas aims to leverage its innovative platform to create therapies that can correct the underlying genetic causes of diseases, with a pipeline that includes both in vivo and ex vivo applications of CRISPR technology.

Editas Medicine (EDIT) Earnings & Revenues

Historic Earnings Reports

EDIT Stock 12 Month Forecast

Average Price Target

$4.14

▲(56.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.44,2.713846153846154,2.9876923076923076,3.2615384615384615,3.5353846153846153,3.809230769230769,4.0830769230769235,4.356923076923077,4.63076923076923,4.904615384615385,5.178461538461539,5.452307692307692,5.726153846153846,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.44,2.5707692307692307,2.7015384615384614,2.832307692307692,2.963076923076923,3.0938461538461537,3.2246153846153844,3.355384615384615,3.486153846153846,3.6169230769230767,3.7476923076923074,3.878461538461538,4.0092307692307685,{"y":4.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.44,2.483076923076923,2.526153846153846,2.569230769230769,2.6123076923076924,2.6553846153846155,2.6984615384615385,2.7415384615384615,2.7846153846153845,2.8276923076923075,2.8707692307692305,2.913846153846154,2.956923076923077,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.2,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >